Agreement provides Premier’s network of more than 4,400 U.S. hospitals and other providers access to LumiraDx’s SARS-CoV-2 Antigen Test and point of care Platform which uses actively controlled microfluidic technology
London, UK – (September 08, 2022) – LumiraDx, Inc., a subsidiary of LumiraDx Limited (Nasdaq: LMDX), a next-generation point of care diagnostics company has been awarded a national group purchasing agreement for the sale and distribution of rapid SARS-CoV-2 Antigen Tests in the United States with Premier, Inc., providing access to Premier’s expansive network of US hospitals and providers. Effective September 1, the new agreement allows Premier members, at their discretion, to take advantage of special pricing and terms pre-negotiated by Premier for LumiraDx’s SARS-CoV-2 Ag Test, run on the LumiraDx point of care Platform.
The LumiraDx SARS-CoV-2 Ag test and LumiraDx Platform use actively controlled microfluidic technology to provide lab-comparable performance at the point of care. In clinical studies, the LumiraDx SARS-CoV-2 Ag test demonstrated a 97.6% positive agreement and 96.6% negative agreement with the PCR reference test for patients within the first twelve days of symptoms, and 100% positive agreement with PCR up to CT 33 1, making it one of the fastest, and most sensitive antigen point of care tests currently commercially available.
Peter Scheu, President, LumiraDx North American Commercial Operations stated, “We are delighted to be awarded this agreement with Premier to provide their network of leading hospitals and healthcare providers access to the LumiraDx SARS-CoV-2 Ag test and point of care Platform.” He continued, “LumiraDx uniquely combines accuracy with speed, which we know is critical in continuing to limit the spread of the virus. In addition, providing fast and trusted results closer to the patient directly increases throughput, and improves patient workflow.”
The LumiraDx Platform consists of a small, portable instrument; microfluidic test strip; simple, standardized workflow; and seamless, secure digital connectivity to the cloud and hospital IT systems. It is being used globally including by the CVS Pharmacy in the US, the National Health Service (NHS) and Boots in the UK, a significant number of accident and emergency rooms globally and is deployed in partnership with the Bill & Melinda Gates Foundation in 50 African countries where access to high-quality diagnostics is limited.
Premier is a leading healthcare improvement company, uniting an alliance of approximately 4,400 U.S. hospitals and 250,000 other providers to transform healthcare. With integrated data and analytics, collaboratives, supply chain solutions, consulting and other services, Premier enables better care and outcomes at a lower cost.
LumiraDx Limited (Nasdaq: LMDX) is a next-generation point of care diagnostics company that is transforming community-based healthcare. Its actively controlled microfluidic technology provides fast, high performance and accessible diagnostic solutions wherever the patient is for nearly any testing scenario, creating unique testing options at the point of need.
The company offers a broad menu of lab comparable tests on a single portable Platform, with more than 30 assays on the market or in development, covering infectious diseases, cardiovascular diseases, diabetes, and coagulation disorders. The company also supports high-complexity laboratory testing in an accessible high-throughput format to leverage current molecular laboratory operations.
Founded in 2014 and based in the UK, LumiraDx's diagnostic testing solutions are being deployed globally by governments and leading healthcare institutions across laboratories, urgent care, physician offices, pharmacies, schools, and workplaces to screen, diagnose, and monitor wellness as well as disease.
More information on LumiraDx is available at www.lumiradx.com.
About the LumiraDx SARS-CoV-2 Antigen Test
The LumiraDx SARS-CoV-2 Antigen test has not been FDA cleared or approved, but has been authorized by FDA under an EUA for use by authorized laboratories. The product has been authorized only for the detection of proteins from SARS-CoV-2, not for any other viruses or pathogens. The emergency use of the product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 360bbb- 3(b)(1), unless the declaration is terminated or authorization is revoked sooner.
Colleen McMillen, VP Communications